HALO Stock: Price, Earnings History and SEC Filings
Halozyme Therapeutics, Inc. (HALO) last traded at $130.91, down 0.21% on the latest session and up 18.6% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $2.17 against an analyst estimate of $1.73, a beat of 25.4%.
$130.91 -0.21%
1 month+18.58%
52-week high$134.00
52-week low$61.23
Volume1.40M
ExchangeNasdaqGS
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
HALO earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Aug 6, 2026 | $2.17 | $1.73 | +25.43% |
| Mar 2026 | May 11, 2026 | $1.48 | $1.46 | +1.37% |
| Dec 2025 | Feb 17, 2026 | $-0.35 | $2.07 | -116.91% |
| Sep 2025 | Nov 3, 2025 | $1.63 | $1.54 | +5.84% |
HALO beat the analyst EPS estimate in 3 of its last 4 reported quarters. Source: Nasdaq.
Latest SEC filings for HALO
SEC filing data is not available right now. You can search for HALO on SEC EDGAR.
HALO news
- Halozyme Therapeutics IncOct 30, 2026 · 247wallst.com
- HALO Gears Up to Report Q3 Earnings: Is a Beat in the Cards?Oct 30, 2026 · finance.yahoo.com
- Exelixis (EXEL) vs. BMRN and NBIX: Can CABOMETYX and Pipeline Growth Revive Investor Confidence?Oct 29, 2026 · finance.yahoo.com
- Halozyme Therapeutics (HALO) Reports Next Week: Wall Street Expects Earnings GrowthOct 29, 2026 · finance.yahoo.com
- What Did Halozyme Stock Investors Miss Before The Run?Oct 28, 2026 · trefis.com
- Strong Royalties and New Launches Accelerate Halozyme Therapeutics’ (HALO) Growth MomentumOct 27, 2026 · finance.yahoo.com
- TNGX Stock Falls 16% Despite Positive Pancreatic Cancer Study DataOct 26, 2026 · finance.yahoo.com
- Incyte & Genmab Collaborate to Develop a New Colorectal Cancer TherapyOct 26, 2026 · finance.yahoo.com
About Halozyme Therapeutics, Inc.
Halozyme Therapeutics, Inc. (HALO) is a US-listed public company on Nasdaq.